看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
, j' h3 |8 t) \, F) Z* H# _4 J. @8 A/ Z- H6 h
! ]% H/ g) r+ f. M. ]6 HCurrently available feasibility data for possible combination strategies. 3 B, [- _! E2 A( |
————————————————————————————————4 R0 W% s6 x: G
Combination Feasibility according to preliminary data 1 N: _# Y5 }( g" r6 A4 ?
——————————————————————————————————
+ ~1 Q3 g' i+ w# N8 }9 G. UBevacizumab + sorafenib Yes, reduced dose
2 l1 R5 i; ~+ i7 `, ?Bevacizumab + sunitinib† No
\5 U" m6 H8 N& [; ?! t% D; t2 CBevacizumab + temsirolimus Yes
' K& c' [1 C( g" w: t! [/ P# TBevacizumab + everolimus Yes
]: Q( R0 U4 X2 n L( iSorafenib + sunitinib ? / S- `& P1 K k$ l9 `
Sorafenib + temsirolimus Yes, reduced dose & N$ B& `+ U6 p0 y4 I
Sorafenib + everolimus Yes, reduced dose 2 c1 w" F; T/ c1 L$ n8 G6 h3 V b) I
Sunitinib + temsirolimus† No
/ {) m l4 T7 g! z/ u8 x: QSunitinib + everolimus ?
6 ?% y. \- ^/ I; _! @3 pTemsirolimus + everolimus ?
4 W/ V" G% e1 {: y7 |————————————————————& J* p) a9 Y8 P+ z3 c
†Led to US FDA warning.
) E6 X3 _, K7 D3 h7 Q+ B6 t" ~- N6 L?: As yet unattempted combination.7 z$ P( q- v8 a4 y6 }$ ~1 X
|
显身卡
6 w1 a1 p. D! P$ d/ a
